Log in
RegisterType-II Variation: Waive in-vivo study by providing in-vitro data? [Study Assessment]
Hello everybody
And as I happen to have the ICH M-9 just in front of me for other reasons, I cite chapter 3 first paragraph:
"A drug product is eligible for a BCS-based biowaiver ... drug product is the same dosage form and strength"
Best regards!
❝ However all of the conditions required for a Class III waiver have to be met and this goes beyond simply showing dissolution similarity.
And as I happen to have the ICH M-9 just in front of me for other reasons, I cite chapter 3 first paragraph:
"A drug product is eligible for a BCS-based biowaiver ... drug product is the same dosage form and strength"
Best regards!
Complete thread:
- Decrease in PSD: Need to repeat BE? qualityassurance 2024-07-02 08:32
![[Mix]](https://static.bebac.at/img/mix.png "open in Mix view")
- Type-II Variation Helmut 2024-07-02 09:37
- Type-II Variation: Waive in-vivo study by providing in-vitro data? qualityassurance 2024-07-02 11:29
- Type-II Variation: Waive in-vivo study by providing in-vitro data? SMA 2024-07-02 16:27
- Type-II Variation: Waive in-vivo study by providing in-vitro data?Relaxation 2024-07-04 12:19
- Type-II Variation: Waive in-vivo study by providing in-vitro data? SMA 2024-07-02 16:27
- Type-II Variation: Waive in-vivo study by providing in-vitro data? qualityassurance 2024-07-02 11:29
- Type-II Variation Helmut 2024-07-02 09:37
Ing. Helmut Schütz